載入中
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company dedicated to the discovery and advancement of genetic treatment modalities, including RNA-targeted therapeutics and gene therapies, specifically for rare diseases. The company currently offers two approved treatments: EXONDYS 51, prescribed for Duchenne muscular dystrophy (DMD) patients with confirmed dystrophin gene mutations amenable to exon 51 skipping, and VYONDYS 53, for DMD patients with exon 53 skipping mutations. Sarepta's development pipeline includes AMONDYS 45, an exon-skipping product candidate utilizing phosphorodiamidate morpholino oligomer chemistry for exon 45; SRP-5051, a peptide-conjugated PMO designed to target exon 51 of dystrophin pre-mRNA; and gene therapy programs such as SRP-9001 for DMD and SRP-9003 for limb-girdle muscular dystrophies. The company maintains collaborative agreements with organizations like F. Hoffman-La Roche Ltd, Nationwide Children's Hospital, Lysogene, Duke University, Genethon, and StrideBio. Founded in 1980, Sarepta Therapeutics is headquartered in Cambridge, Massachusetts.
前收盤價
US$17.44
−US$0.41 · -2.30%
盤前
US$17.77
+US$0.33 · +1.89%
10月13日 上午4:01 ET
盤中時間採用ET。市場資料可能有所延遲。
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company dedicated to the discovery and advancement of genetic treatment modalities, including RNA-targeted therapeutics and gene therapies, specifically for rare diseases. The company currently offers two approved treatments: EXONDYS 51, prescribed for Duchenne muscular dystrophy (DMD) patients with confirmed dystrophin gene mutations amenable to exon 51 skipping, and VYONDYS 53, for DMD patients with exon 53 skipping mutations. Sarepta's development pipeline includes AMONDYS 45, an exon-skipping product candidate utilizing phosphorodiamidate morpholino oligomer chemistry for exon 45; SRP-5051, a peptide-conjugated PMO designed to target exon 51 of dystrophin pre-mRNA; and gene therapy programs such as SRP-9001 for DMD and SRP-9003 for limb-girdle muscular dystrophies. The company maintains collaborative agreements with organizations like F. Hoffman-La Roche Ltd, Nationwide Children's Hospital, Lysogene, Duke University, Genethon, and StrideBio. Founded in 1980, Sarepta Therapeutics is headquartered in Cambridge, Massachusetts.
日內區間
目前US$17.44
52週區間
目前US$17.44
盤中時間採用ET。市場資料可能有所延遲。
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company dedicated to the discovery and advancement of genetic treatment modalities, including RNA-targeted therapeutics and gene therapies, specifically for rare diseases. The company currently offers two approved treatments: EXONDYS 51, prescribed for Duchenne muscular dystrophy (DMD) patients with confirmed dystrophin gene mutations amenable to exon 51 skipping, and VYONDYS 53, for DMD patients with exon 53 skipping mutations. Sarepta's development pipeline includes AMONDYS 45, an exon-skipping product candidate utilizing phosphorodiamidate morpholino oligomer chemistry for exon 45; SRP-5051, a peptide-conjugated PMO designed to target exon 51 of dystrophin pre-mRNA; and gene therapy programs such as SRP-9001 for DMD and SRP-9003 for limb-girdle muscular dystrophies. The company maintains collaborative agreements with organizations like F. Hoffman-La Roche Ltd, Nationwide Children's Hospital, Lysogene, Duke University, Genethon, and StrideBio. Founded in 1980, Sarepta Therapeutics is headquartered in Cambridge, Massachusetts.
日內區間
目前US$17.44
52週區間
目前US$17.44
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 21.98億 USD | 19.02億 USD | 12.43億 USD | 9.33億 USD | 7.02億 USD |
| 銷貨成本 | 8.82億 USD | 3.19億 USD | 1.5億 USD | 1.4億 USD | 9704.9萬 USD |
| 毛利 | 13.17億 USD | 15.83億 USD | 10.93億 USD | 7.93億 USD | 6.05億 USD |
| 研究與開發 | 15.22億 USD | 8.05億 USD | 8.77億 USD | 8.77億 USD | 7.71億 USD |
| 銷售、一般及管理費用 | 4.79億 USD | 5.58億 USD | 4.82億 USD | 4.51億 USD | 2.83億 USD |
| 營業費用 | 19.75億 USD | 13.65億 USD | 13.61億 USD | 13.29億 USD | 10.65億 USD |
| 利息收入 | 1956.9萬 USD | 7176.7萬 USD | 8596.9萬 USD | 2772.3萬 USD | 51.1萬 USD |
| 利息支出 | 973.1萬 USD | 1839.1萬 USD | 2201萬 USD | 5324.8萬 USD | 6352.5萬 USD |
| 折舊和攤銷 | 4452.1萬 USD | 3772.4萬 USD | 4439.7萬 USD | 4186.4萬 USD | 3801.7萬 USD |
| 營業利益 | −6.58億 USD | 2.18億 USD | −2.68億 USD | −5.36億 USD | −4.6億 USD |
| 淨利 | −7.13億 USD | 2.35億 USD | −5.36億 USD | −7.03億 USD | −4.19億 USD |
公司資料更新於 2026年10月13日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$21.60
上漲空間 23.85%報告持有此股票曝險的交易所交易基金。
First Trust NYSE Arca Biotechnology Index FundFBT8528.1萬2.95%28.91億 USD0.55%US$263.9-0.57%
Vanguard Morningstar Total Stock Market ETFVTI6718.61萬0.00%2.3兆 USD0.03%US$381.57-0.10%
State Street SPDR S&P Biotech ETFXBI5201.53萬0.53%103.03億 USD0.35%US$151.4-1.54%
Vanguard Morningstar Small-Cap ETFVB4849.45萬0.03%1853億 USD0.03%US$288.16-0.46%
iShares Russell 2000 ETFIWM4845.16萬0.06%787.4億 USD0.19%US$277.9-0.37%
Vanguard Morningstar Small-Cap Growth ETFVBK2778.35萬0.06%447億 USD0.05%US$340.88-1.12%
Vanguard Extended Market ETFVXF2584.23萬0.03%954億 USD0.05%US$233.52-0.63%
State Street SPDR Portfolio S&P 600 Small Cap ETFSPSM1735.73萬0.11%157.12億 USD0.03%US$53.42-0.06%First Trust NYSE Arca Biotechnology Index FundFBTVanguard Morningstar Total Stock Market ETFVTIState Street SPDR S&P Biotech ETFXBIVanguard Morningstar Small-Cap ETFVBiShares Russell 2000 ETFIWMVanguard Morningstar Small-Cap Growth ETFVBKVanguard Extended Market ETFVXFState Street SPDR Portfolio S&P 600 Small Cap ETFSPSMAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
